{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Carcinoma&page=7", "query": { "condition": "Metastatic Breast Carcinoma", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 2114, "total_pages": 212, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Carcinoma&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Carcinoma&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T12:59:14.351Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006381", "title": "Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "celecoxib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2000-06", "completion_date": "2004-02", "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-10-13T12:59:14.351Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006381" }, { "nct_id": "NCT05933265", "title": "Study of LP-184 in Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "GBM", "TNBC - Triple-Negative Breast Cancer", "NSCLC", "Pancreatic Adenocarcinoma", "DDR Gene Mutation" ], "interventions": [ { "name": "LP-184", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Nivolumab & Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lantern Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2023-06-09", "completion_date": "2026-07-28", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-13T12:59:14.351Z", "location_count": 7, "location_summary": "Springdale, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 4 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05933265" }, { "nct_id": "NCT02892734", "title": "Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2/Neu Negative", "Recurrent Inflammatory Breast Carcinoma", "Stage IV Breast Cancer", "Stage IV Inflammatory Breast Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2017-09-18", "completion_date": "2019-02-04", "has_results": true, "last_update_posted_date": "2020-07-16", "last_synced_at": "2026-10-13T12:59:14.351Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02892734" }, { "nct_id": "NCT00379509", "title": "Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "TdT-mediated dUTP nick end labeling assay", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 20, "start_date": "2006-04", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2017-03-21", "last_synced_at": "2026-10-13T12:59:14.351Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00379509" }, { "nct_id": "NCT00496366", "title": "Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer", "HER2/Neu-positive Breast Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2007-07-23", "completion_date": "2017-03-20", "has_results": true, "last_update_posted_date": "2017-03-21", "last_synced_at": "2026-10-13T12:59:14.351Z", "location_count": 2, "location_summary": "Hamilton, New Jersey • New Brunswick, New Jersey", "locations": [ { "city": "Hamilton", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00496366" }, { "nct_id": "NCT00722072", "title": "Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "fulvestrant", "type": "DRUG" }, { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 12, "start_date": "2008-07", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2018-02-26", "last_synced_at": "2026-10-13T12:59:14.351Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00722072" }, { "nct_id": "NCT02706392", "title": "Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Mantle Cell Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Stage III Lung Non-Small Cell Cancer AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7", "Unresectable Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "ROR1 CAR-specific Autologous T-Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2016-03-16", "completion_date": "2021-09-28", "has_results": true, "last_update_posted_date": "2022-08-31", "last_synced_at": "2026-10-13T12:59:14.351Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02706392" }, { "nct_id": "NCT02988648", "title": "A Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I Symporter", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Radioiodide (131I-)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 0, "start_date": "2016-12", "completion_date": "2018-01", "has_results": false, "last_update_posted_date": "2018-08-22", "last_synced_at": "2026-10-13T12:59:14.351Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02988648" }, { "nct_id": "NCT02139358", "title": "Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2014-09-05", "completion_date": "2020-03-16", "has_results": true, "last_update_posted_date": "2021-02-04", "last_synced_at": "2026-10-13T12:59:14.351Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02139358" }, { "nct_id": "NCT07227233", "title": "Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant.", "type": "DRUG" }, { "name": "Treatment of physician's choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2026-03-31", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-10-13T12:59:14.351Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227233" } ] }